Aktis Oncology, Inc. Common stock (AKTS) — Capital Reinvestment Ratio
Aktis Oncology, Inc. Common stock (AKTS) has a Capital Reinvestment Ratio of 0.19x as of December 2024, meaning it reinvests 0% of its operating cash flow ($14.76 Million) in capital expenditures ($2.86 Million). Check Aktis Oncology, Inc. Common stock tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Aktis Oncology, Inc. Common stock Capital Reinvestment Ratio (2024–2024)
This chart tracks Aktis Oncology, Inc. Common stock's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Aktis Oncology, Inc. Common stock operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Aktis Oncology, Inc. Common stock (2024–2024)
Year-by-year Capital Reinvestment Ratio for Aktis Oncology, Inc. Common stock from 2024 to 2024. See Aktis Oncology, Inc. Common stock free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.19x | $14.76 Million | $2.86 Million | — |